(Q41548711)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author

Silvio Marco Veronese

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Roberto Labianca

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Eliana Rulli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mirko Marabese

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Luca Moscetti

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Monica Ganzinelli

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Silvia Marsoni

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Massimo Broggini

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Marina Garassino

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

V Torri

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

G Farina

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

A Bettini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

F Longo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

C Lauricella

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

E Copreni

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

O Martelli

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

TAILOR trialists

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

24 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

2079-2084

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

RAS oncogenes: weaving a tumorigenic web

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

KRAS mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Across the universe of K-RAS mutations in non-small-cell-lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

KRAS mutations as prognostic and predictive markers in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Are all KRAS mutations created equal?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Testing epidermal growth factor receptor mutations in patients with non-small-cell lung cancer to choose chemotherapy: the other side of the coin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor recep

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Comprehensive molecular profiling of lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Non-small-cell lung cancers: a heterogeneous set of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

MEK inhibition in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV318

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV318

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26209642%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference